Genmab — December 2022
-
-
rest of the schedule by the way: https://ir.genmab.com/news-releases/news-release-details/genmab-announces-multiple-abstracts-be-presented-64th-annual
-
ASH tråd. Fyld gerne på: https://www.proinvestor.com/boards/108608/
-
Rafineret teknologi viser gode resultater. Dejligt med de mange fremskridt i cancerbehandling https://www.bbc.com/news/health-63859184
-
Ham her har visse indvendinger imod talq-studiet: https://www.youtube.com/watch?v=PAvLpjVstOk
-
Den første del af kritikken er svært for lægmand at vurdere. Håber at nogen af vore eksperter kan byde ind. Det med det uetiske med den homøopatiske dosering i lavdosisgruppen er til gengæld nemt for de fleste at forstå og være enig i. Det er jeg i hvert fald.
-
Han er i hvert fald ikke begejstret for car-t. Og så peger han også på bivirkninger. Infektioner af tec og udslet på huden af talq. Men som han selv siger, der er en pris at betale. Om man skulle gå direkte til randomiserede studier fra fase 1, kan jeg ikke vurdere. Men hvis det var muligt, ville fda vel have krævet det.
-
Prasad er vist en lidt kontroversiel person https://tuftsdaily.com/news/2022/03/08/controversial-oncologist-dr-vinay-prasad-disavowed-by-dean-lectures-to-gsbs/
-
Epcoritamab+RDHAX/C: quickly effective and well tolerated in rrDLBCL in the EPCORE NHL-2 study https://twitter.com/amniebla/status/1601982162168954882?s=61&t=xIDx9wxi6oZSGwmTiFu4wQ
-
Epcoritamab CD20×CD3 with DHAX, n=29, 66% primary refractory, 21 pts responded and 16 proceeded to AutoSCT, ORR 85%, 67% CR https://twitter.com/abhinav_deol/status/1601981658252836866?s=61&t=xIDx9wxi6oZSGwmTiFu4wQ
-
sc Epcoritamab+R-DHAC/X
in RR DLBCL ASCT eligible
Ph 1/2
N=29 58y (28-75)
16 pts had ASCT after 3 cycles
5 continued epco without ASCTCR 81% in ASCT pts 45% in no ASCT
Short Fu 12.6 mo PFS NRV active combo (more than Pola-RICE) https://twitter.com/pallawitorkamd/status/1601981858778329088?s=61&t=xIDx9wxi6oZSGwmTiFu4wQ
-
Promising activity of Epcoritamab + RDHAX/C in transplant eligible DLBCL. ORR 85%, and CR 67%. mPFS and OS not reached. This could be a potential bridging regimen. https://twitter.com/dipenkmodi/status/1601982359041380352?s=61&t=xIDx9wxi6oZSGwmTiFu4wQ
-
Improvement in the quality of response to salvage CIT adding Epcoritamab in DLBCL patients eligible for HDT/ASCT https://twitter.com/asernapareja/status/1601982543502446592?s=61&t=xIDx9wxi6oZSGwmTiFu4wQ
-
Impressive results with Epcoritamab in r/r DLBCL high response rate & excellent PFS/OS https://twitter.com/drmiguelperales/status/1601982759920173063?s=61&t=xIDx9wxi6oZSGwmTiFu4wQ
-
epcoritamab again looks like the one to beat. 21 May 2023 Pdufa date. Meanwhile, $RHHBY due to file glofitamab by YE 2022. $REGN presenting odronextamab data at #ASH22 right now. Can step-up dosing mitigate the tox here? https://twitter.com/jacobplieth/status/1601983713176391683?s=61&t=xIDx9wxi6oZSGwmTiFu4wQ
-
Generelt meget positiv evaluering af epco. Men ligeså af glofi. Så den største fordel for Genmab/Abbvie er nok at de fra starten valgte at gå subcu vejen.
-
Odrontextamab fra REGN er ikke nær så god pga dårlig tox profile
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind